President Trump's nominee for health secretary, Robert F. Kennedy Jr., was questioned harshly by both Democrats and ...
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
Cedar Rapids KCRG-TV on MSN13h
State lawmakers to consider Pharmacy Benefit Manager reform after 29 Iowa pharmacies closed in 2024Bills in the Iowa House and Senate would change how pharmacy benefit managers, or PBMs, mediate pharmacies and insurance ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...
Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.
Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback